Kevin Kalinsky, MD, MS, on Implications of the Phase 3 RxPONDER Trial in Breast Cancer

The breast medical oncologist and researcher discussed how the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal, lymph node-positive, HR-positive, HER2-negative breast cancer.

A study presented at the 2020 San Antonio Breast Cancer Symposium found that menopausal status may determine clinical benefit from the addition of chemotherapy to endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine; director of the Glenn Family Breast Center and director of breast medical oncology at Winship Cancer Institute of Emory University, spoke to CancerNetwork about the trial results and their implications.


So, I think that this study is practice changing. And I think that for the postmenopausal group, when you look at two-thirds of the population, when you look at those curves, they fully overlap. There was a hazard ratio of 0.97 and those curves look exactly the same. And there was no benefit even when we did a forest plot of any subgroups and postmenopausal women who are benefiting from chemo. So, for the postmenopausal group, you know, that spares thousands of women, the cost and the toxicity, and all the other issues that can be associated with getting chemotherapy.

Now in the premenopausal group, there was a statistically significant improvement within invasive disease-free survival and also a 1.3% absolute improvement in survival in the group that were randomized to chemotherapy. So you know, that has huge implications for when we sit down with our patients, and we explain to them, “Well, listen, these are the benefits and these are the risks.” This study helps inform those discussions.

Related Videos
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
Experts on breast cancer
Experts on breast cancer
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Experts on breast cancer
Hope S. Rugo, MD, an expert on breast cancer
Related Content